Nebivolol Inhibits Human Aortic Smooth Muscle Cell Growth: Effects on Cell Cycle Regulatory Proteins
An enhanced vasoconstriction and vascular smooth muscle cell proliferation are involved in pathogenesis of hypertension. β-Blockers are effective for treatment of hypertensive patients. Recently the new β1-receptor blocker nebivolol showed a different hemodynamic profile from those of other classic...
Gespeichert in:
Veröffentlicht in: | Journal of cardiovascular pharmacology 2000-06, Vol.35 (6), p.845-848 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | An enhanced vasoconstriction and vascular smooth muscle cell proliferation are involved in pathogenesis of hypertension. β-Blockers are effective for treatment of hypertensive patients. Recently the new β1-receptor blocker nebivolol showed a different hemodynamic profile from those of other classic β-blockers. In this study we hypothesized that nebivolol may also have different effects on smooth muscle cell proliferation compared with other β-blockers such as atenolol. Human aortic smooth muscle cells (SMCs) were cultured, and cell growth was determined by increase in cell number. Growth-signaling molecules such as mitogen-activated protein kinase (p42) and S6-kinase (p70) and cell-cycle regulatory proteins (i.e., Cdk2, p27, and pRb) were analyzed by immunoblotting. In cultured human aortic SMCs, cell number was markedly increased in response to 5% fetal calf serum (FCS) over 6 days (87 ± 11 × 10/well), which was inhibited by nebivolol (10−10 M; 25 ± 2 × 10/well; n = 6; p < 0.05), but not by atenolol. 5% FCS activated p42, S6K, and Cdk2, but downregulated p27 and hyperphosphorylated pRb. Nebivolol prevented Cdk2 activation without influencing p42, S6K, pRB, and p27. Thus, the new β1-blocker nebivolol exhibits antiproliferative effect on human SMC through inactivation of Cdk2. This effect of nebivolol may have advantages over other β-blockers in treatment of patients with cardiovascular disease. |
---|---|
ISSN: | 0160-2446 1533-4023 |
DOI: | 10.1097/00005344-200006000-00003 |